Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|October 20, 2012
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenibJ L Kuiper, J S W Lind, H J M Groen, et al.
British Journal of Cancer|May 20, 2004
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumoursF M Wachters, H J M Groen, J G Maring, et al.
Lung Cancer (Amsterdam, Netherlands)|May 26, 2012
Blinded and uniform cause of death verification in a lung cancer CT screening trialN Horeweg, R J van Klaveren, H J M Groen, et al.
The Netherlands Journal of Medicine|June 28, 2017
Transient thyrotoxicosis during nivolumab treatmentM J van Kooten, G van den Berg, A W J M Glaudemans, et al.
Scientific Reports|April 21, 2023
Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancerH C Donker, B van Es, M Tamminga, et al.
Lung Cancer (Amsterdam, Netherlands)|July 8, 2023
Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancerH C Donker, K Cuppens, G Froyen, et al.
Anticancer Research|October 30, 2004
Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II studyM A Stokman, F M Wachters, P Koopmans, et al.
European Journal of Cancer (Oxford, England : 1990)|December 27, 2016
Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trialO P Geerse, J E H M Hoekstra-Weebers, M H Stokroos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2013
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 studyJ G Aerts, H Codrington, N A G Lankheet, et al.
British Journal of Cancer|April 16, 2002
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD geneJ G Maring, A B P van Kuilenburg, J Haasjes, et al.
Pageof 7